Epidermicin NI01 - Amprologix
Latest Information Update: 13 Oct 2023
At a glance
- Originator Plymouth University; University of Manchester
- Class Antibacterials; Antimicrobial cationic peptides; Bacteriocins; Recombinant proteins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 13 Oct 2023 Epidermicin NI01 is still in preclinical development for Staphylococcus aureus infections in United Kingdom (Amprologix website, October 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in United Kingdom (Topical, Cream)
- 05 Feb 2019 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections are still ongoing in United Kingdom (Topical)